Cencora (NYSE:COR) Releases FY 2026 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 17.450-17.600 for the period, compared to the consensus earnings per share estimate of 17.610. The company issued revenue guidance of $343.8 billion-$350.2 billion, compared to the consensus revenue estimate of $340.7 billion.

Analysts Set New Price Targets

COR has been the subject of several analyst reports. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Wells Fargo & Company increased their target price on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Finally, Bank of America decreased their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $396.92.

Cencora Stock Down 3.8%

Cencora stock opened at $351.91 on Friday. The stock has a fifty day simple moving average of $347.08 and a two-hundred day simple moving average of $327.83. The firm has a market cap of $68.27 billion, a price-to-earnings ratio of 42.30, a PEG ratio of 1.69 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora has a 12 month low of $237.71 and a 12 month high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the business posted $3.73 earnings per share. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. Equities analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This represents a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 20,316 shares of company stock worth $7,151,265. Company insiders own 0.38% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of COR. Marshall Wace LLP increased its holdings in shares of Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after purchasing an additional 1,672,762 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Cencora by 528.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after buying an additional 1,241,186 shares during the last quarter. Viking Global Investors LP boosted its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after acquiring an additional 1,013,913 shares in the last quarter. State Street Corp lifted its stake in Cencora by 9.3% during the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after purchasing an additional 782,911 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Cencora by 228.6% in the second quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock valued at $292,207,000 after purchasing an additional 677,952 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.